clinical trial · NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S·phase3·not yet recruiting·n = 80
Diabetes Mellitus, Type 2CagriSema (Cagrilintide B and Semaglutide I)Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
brief summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
started
Aug 4, 2026
primary completion
Sep 7, 2029
completion
Mar 30, 2030
last updated
Mar 30, 2026
official title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol